<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02552966</url>
  </required_header>
  <id_info>
    <org_study_id>STU00201370</org_study_id>
    <nct_id>NCT02552966</nct_id>
  </id_info>
  <brief_title>Assessing the Impacts of a UESAD on Laryngeal Symptoms and Salivary Pepsin</brief_title>
  <official_title>Assessing the Impacts of an Upper Esophageal Sphincter Assist Device on Laryngeal Symptoms and Salivary Pepsin: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Somna Therapeutics, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is postulated that the incompetence of the upper esophageal sphincter (UES) to restrict
      passage of esophageal refluxate is fundamental to the development of LPR. The UES Assist
      Device (UESAD) is a novel device that applies relatively modest external cricoid pressure,
      which results in a 20 to 30 mmHg intraluminal UES pressure increase. Pepsin, a proteolytic
      enzyme produced in the stomach, has been detected in the laryngeal epithelium of patients
      with reflux associated laryngeal symptoms and implicated in the pathogenesis of
      laryngopharyngeal reflux. This study will assess the effectiveness of a UESAD worn for 2
      weeks on LPR symptoms and salivary pepsin levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A cost-effective and care appropriate algorithm to streamline the diagnosis and management of
      patients with laryngopharyngeal reflux (LPR) has not been described. It is postulated that
      the incompetence of the upper esophageal sphincter (UES) to restrict passage of esophageal
      refluxate is fundamental to the development of LPR. The UES Assist Device (UESAD) is a novel
      device that applies relatively modest external cricoid pressure, which results in a 20 to 30
      mmHg intraluminal UES pressure increase. Pepsin, a proteolytic enzyme produced in the
      stomach, has been detected in the laryngeal epithelium of patients with reflux associated
      laryngeal symptoms and implicated in the pathogenesis of laryngopharyngeal reflux. A study
      examining salivary pepsin levels for patients pre- and post-fundoplication for LPR found that
      all patients with positive preoperative pepsin levels and postoperative elimination had
      symptom improvement, suggesting that changes in pepsin level may be reflective of surgical
      responsiveness. This study seeks to explore the therapeutic role of the UESAD in patients
      with LPR symptoms, and measure its effectiveness by objective criteria (salivary pepsin) and
      symptomatic improvement. In this study, 25 patients seen in GI clinic with laryngeal
      complaints will complete validated symptom questionnaires - the RSI, GerdQ and N-GSSIQ
      scores. Those with an RSI &gt; 13 and GerdQ &gt; 8 will be included. They will submit 3 baseline
      sputum samples for pepsin analysis, taken upon awaking. They will then be advised to use the
      UESAD nightly for 2 weeks. 3 follow-up sputum samples for pepsin analysis will be taken and
      symptom scores reevaluated after the 2 week period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2015</start_date>
  <completion_date type="Actual">August 31, 2018</completion_date>
  <primary_completion_date type="Actual">August 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Salivary Pepsin Concentration</measure>
    <time_frame>2 weeks</time_frame>
    <description>Average salivary pepsin concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RSI Score</measure>
    <time_frame>2 weeks</time_frame>
    <description>Respiratory symptom index (RSI) score. Values between 0 and 45. Higher value is associated with increased symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GerdQ Score</measure>
    <time_frame>2 weeks</time_frame>
    <description>GERDQ score. Scale of 0-12, higher score indicates increased symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NGSSIQ Score</measure>
    <time_frame>2 weeks</time_frame>
    <description>NGSSI questionnaire score</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Laryngopharyngeal Reflux</condition>
  <arm_group>
    <arm_group_label>UESAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Upper Esophageal Sphincter Assist Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UESAD</intervention_name>
    <description>Device designed to provide modest cricoid pressure to reduce reflux</description>
    <arm_group_label>UESAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female persons age 18-90

          2. Patients with LPR symptoms (RSI &gt;13)

        Exclusion Criteria:

          1. Pregnant patients per history on initial evaluation.

          2. Adults unable to consent in English

          3. Patients who are currently imprisoned

          4. Patients started on PPI therapy within 4 weeks of study

          5. Patients with implants or implant parts that reside in the area where the REZA BAND is
             applied.

          6. Patients with an implanted pacemaker, implanted cardioverter defibrillator (ICD),
             vagus nerve stimulator, or other such similar devices implanted in the neck.

          7. Patients diagnosed with glaucoma.

          8. Patients who had a malignancy of the neck, including neck surgery.

          9. Patients that may have an altered mental status including due to the use of sedative
             drugs or narcotics.

         10. Patients with carotid artery disease, thyroid disease, a history of cerebrovascular
             disease, or any disorder of connective tissues (e.g., Marfan's Syndrome or
             Ehlers-Danlos Syndrome).

         11. Patients who use nocturnal NIV machines such as CPAP or BiPAP.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John E Pandolfino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <reference>
    <citation>El-Serag HB, Lee P, Buchner A, Inadomi JM, Gavin M, McCarthy DM. Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol. 2001 Apr;96(4):979-83.</citation>
    <PMID>11316215</PMID>
  </reference>
  <reference>
    <citation>Francis DO, Rymer JA, Slaughter JC, Choksi Y, Jiramongkolchai P, Ogbeide E, Tran C, Goutte M, Garrett CG, Hagaman D, Vaezi MF. High economic burden of caring for patients with suspected extraesophageal reflux. Am J Gastroenterol. 2013 Jun;108(6):905-11. doi: 10.1038/ajg.2013.69. Epub 2013 Apr 2.</citation>
    <PMID>23545710</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <results_first_submitted>June 11, 2019</results_first_submitted>
  <results_first_submitted_qc>February 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2020</results_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>John Pandolfino</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Laryngopharyngeal Reflux</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 13, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT02552966/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the Northwestern Medicine Gastroenterology clinic during the study period beginning 9/1/2015. A total of 15 subjects</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>UESAD</title>
          <description>Upper Esophageal Sphincter Assist Device
UESAD: Device designed to provide modest cricoid pressure to reduce reflux</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>UESAD</title>
          <description>Upper Esophageal Sphincter Assist Device
UESAD: Device designed to provide modest cricoid pressure to reduce reflux</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.7" lower_limit="27" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GERDQ</title>
          <description>GastroEsophageal Reflux Disease Questionnaire (GERDQ). This scale measures symptom burden of gastroesophageal reflux disease (GERD). A higher score indicated greater symptom severity on a scale of 0 to 18. No subscales are combined to compute the total score. &quot;Units on a scale&quot; is the appropriate Unit of Measure.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.4" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Reflux Symptom Index (RSI)</title>
          <description>Reflux Symptom Index (RSI). This questionnaire measures laryngeal symptom severity for subjects experiencing reflux-related laryngeal symptoms (e.g. sore throat, throat clearing, post nasal drip, globus and cough). A higher score indicates greater severity on a scale of 0 to 45. No subscales are used to compute a total score. &quot;Units on a scale&quot; is the appropriate unit of measure for this questionnaire.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.0" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NGSSIQ</title>
          <description>Nocturnal GERD Symptom Severity &amp; Impact Questionnaire (NGSSIQ). This questionnaire assesses nighttime symptom severity and the impact of nighttime GERD symptoms. A higher scoe indicates greater severity on a scale of 0 to 60. No subscales were used to calculate the composite score. &quot;Units on a scale&quot; is the appropriate unit of measure for this questionnaire.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.4" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pepsin (ng/mL)</title>
          <description>Salivary Pepsin (referred to as &quot;pepsin&quot;) is a biomarker measured in this study in ng/mL.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146.5" spread="172.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Salivary Pepsin Concentration</title>
        <description>Average salivary pepsin concentration</description>
        <time_frame>2 weeks</time_frame>
        <population>Twelve subjects provided post-treatment salivary samples for pepsin analysis. While the subject flow shows 20 subjects (all of which completed baseline pepsin analysis), only 12 completed post-treatment testing.</population>
        <group_list>
          <group group_id="O1">
            <title>UESAD</title>
            <description>Upper Esophageal Sphincter Assist Device
UESAD: Device designed to provide modest cricoid pressure to reduce reflux</description>
          </group>
        </group_list>
        <measure>
          <title>Salivary Pepsin Concentration</title>
          <description>Average salivary pepsin concentration</description>
          <population>Twelve subjects provided post-treatment salivary samples for pepsin analysis. While the subject flow shows 20 subjects (all of which completed baseline pepsin analysis), only 12 completed post-treatment testing.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.4" spread="150.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.61</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>This t-test was applied to determine if the mean salivary pepsin concentration changed between baseline and 2 week post UESAD measurements.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RSI Score</title>
        <description>Respiratory symptom index (RSI) score. Values between 0 and 45. Higher value is associated with increased symptom severity.</description>
        <time_frame>2 weeks</time_frame>
        <population>15 subjects completed the RSI post-treatment. The subject flow shows 20 subjects completing this questionnaire at baseline, but this section reflects the 15 subjects who completed this questionnaire post-treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>UESAD</title>
            <description>Upper Esophageal Sphincter Assist Device
UESAD: Device designed to provide modest cricoid pressure to reduce reflux</description>
          </group>
        </group_list>
        <measure>
          <title>RSI Score</title>
          <description>Respiratory symptom index (RSI) score. Values between 0 and 45. Higher value is associated with increased symptom severity.</description>
          <population>15 subjects completed the RSI post-treatment. The subject flow shows 20 subjects completing this questionnaire at baseline, but this section reflects the 15 subjects who completed this questionnaire post-treatment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GerdQ Score</title>
        <description>GERDQ score. Scale of 0-12, higher score indicates increased symptom severity.</description>
        <time_frame>2 weeks</time_frame>
        <population>Fifteen subjects completed the post-treatment GERDQ questionnaire. While 20 subjects completed the questionnaire at baseline, this section contains results from the 15 who completed the questionnaire 2 weeks post UESAD treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>UESAD</title>
            <description>Upper Esophageal Sphincter Assist Device
UESAD: Device designed to provide modest cricoid pressure to reduce reflux</description>
          </group>
        </group_list>
        <measure>
          <title>GerdQ Score</title>
          <description>GERDQ score. Scale of 0-12, higher score indicates increased symptom severity.</description>
          <population>Fifteen subjects completed the post-treatment GERDQ questionnaire. While 20 subjects completed the questionnaire at baseline, this section contains results from the 15 who completed the questionnaire 2 weeks post UESAD treatment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NGSSIQ Score</title>
        <description>NGSSI questionnaire score</description>
        <time_frame>2 weeks</time_frame>
        <population>Fifteen subjects completed the post-treatment questionnaire. While 20 subjects (as indicated on the participant flow section) completed the baseline questionnaire, this section reflects the results of the 15 subjects who completed the questionnaire at 2 weeks post UESAD treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>UESAD</title>
            <description>Upper Esophageal Sphincter Assist Device
UESAD: Device designed to provide modest cricoid pressure to reduce reflux</description>
          </group>
        </group_list>
        <measure>
          <title>NGSSIQ Score</title>
          <description>NGSSI questionnaire score</description>
          <population>Fifteen subjects completed the post-treatment questionnaire. While 20 subjects (as indicated on the participant flow section) completed the baseline questionnaire, this section reflects the results of the 15 subjects who completed the questionnaire at 2 weeks post UESAD treatment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 days</time_frame>
      <desc>adverse events were collected throughout the study</desc>
      <group_list>
        <group group_id="E1">
          <title>UESAD</title>
          <description>Upper Esophageal Sphincter Assist Device
UESAD: Device designed to provide modest cricoid pressure to reduce reflux</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. John Pandolfino, Principal Investigator</name_or_title>
      <organization>Northwestern University</organization>
      <phone>3126950182</phone>
      <email>j-pandolfino@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

